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INTRODUCTION
Uncontrolled cell proliferation is the hallmark of cancer,
and tumor cells have acquired damage to genes that directly
regulate their cell cycles. In the cell cycle, the period from
the late G1 to the S phase is the most important for cell
proliferation. The decision to divide occurs as cell passes a
restriction point late in G1, after which they commit to the
autonomous program that carries them through to division.
The restriction point is regulated largely by retinoblastoma
gene product (pRb). In pRb phosphorylation, two major
G1 cyclins have important roles. Cylin D1 forms a complex
with cyclin-dependent kinase (cdk) 4 or cdk6, and works
for the phosphorylation of pRb. Cyclin E binds to cdk2 and
also phosphorylates pRb (1). Cyclin D1 gene is amplified in
human carcinomas of esophagus (2) and breast (3). Deran-
ged cyclin E mRNA expression has been reported in carci-
nomas of the breast (4). Rb gene is deleted or mutated in a
wide range of human cancers (5).
To prevent unrestrained proliferation, there are a number
of cyclin-dependent kinase inhibitors (CKIs) which bind
with specific cdks, preventing the cdks from binding to
cyclin and hence blocking a cascade of events which ulti-
mately leads to cell proliferation. Two subtypes of CKIs are
the INK (inhibitor of kinase) family, which includes p16
(INK4a), p15 (INK4b), p18 (INK4c) and p19 (INK4d),
and the CIP/KIP (cdk interacting protein/kinase inhibitory
protein) family, which includes p21 (WAF1/CIP1), p27
(KIP1) and p57 (KIP2) (6). After exposure to DNA damag-
ing agent, wild-type p53 induced p21 protein expression
allows apoptosis, thus, induction of p21 protein seems to
occur with functional p53. In contrast, recent study has
demonstrated that p21 can be induced by a p53-indepen-
dent pathway (7). p16 is implicated in carcinogenesis as a
result of frequent gene alterations such as deletion, muta-
tion, and aberrant DNA methylation in human cancers (8).
Unlike p16 gene, mutation of the p21 or p27 gene is an
extremely rare event in human carcinomas (9-11).
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Expression of the G1-S Modulators in Hepatitis B Virus-Related 
Hepatocellular Carcinoma and Dysplastic Nodule: Association of Cyclin 
D1 and p53 Proteins with the Progression of Hepatocellular Carcinoma
Deranged expression of cell cycle modulators has been reported to contribute to
the development and progression of hepatocellular carcinoma (HCC). However,
their expression patterns remain poorly understood in hepatitis B virus (HBV)-
related HCC, which constitutes about 65-70% of HCC in Korea. The aims of this
study were to evaluate the expressions of G1-S modulators in HBV-related HCCs
and dysplastic nodules (DNs), and to correlate with the histopathologic features of
HCCs. Immunohistochemical expressions of cyclin D1, cyclin E, p53, p27, p21,
p16, Rb, and PCNA proteins were investigated in 80 HCCs and 22 DNs. Cyclin
D1 overexpression showed positive relationships with advanced tumor stage,
poor differentiation, larger tumor size, microvascular invasion, intrahepatic meta-
stasis, no tumor capsule formation, infiltrative growth, aberrant p53 expression,
and high PCNA labeling index (LI) of HCC (p<0.05). Aberrant p53 expression
showed positive relationship with poor differentiation of HCC (p<0.01). Expression
of cyclin D1 or p53 was not observed in DNs. The p27 LI and p16 LI were lower in
HCCs with intrahepatic metastasis (p<0.05). Cyclin D1 overexpression and aber-
rant p53 expression could be associated with the progression of HBV-related
HCC, and might have a less crucial role in the DN-HCC sequence. In addition,
elevated expression of p27 and p16 proteins might have inhibitory action to the
intrahepatic metastasis of HBV-related HCC.
Key Words : Carcinoma, Hepatocellular; Dysplastic Nodule; Hepatitis B Virus; Protein cyclin D1; Pro-
tein p53; Protein p27; Protein p16
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p53 is considered to be a stress response gene, and its
product (the p53 protein) induces cell cycle arrest or apop-
tosis in response to DNA damage. Mutation of p53 gene is
the most common genetic abnormality identified in human
carcinomas and may result in a biologically altered protein
that is detectable by immunohistochemical method (12).
Proliferating cell nuclear antigen (PCNA) is an auxiliary
protein for DNA polymerase-delta, and accumulates in the
nucleus from the late G1 to the S phase. PCNA can be used
as an immunohistochemical marker of proliferating cells (13).
Hepatocellular carcinoma (HCC) is one of the most com-
mon human malignancies, especially in sub-Saharan Africa
and Southeast Asia including Korea (14). Hepatitis B and C
viruses, alcohol and aflatoxin B1 are known risk factors for
HCC. It is probable that the ongoing process of hepatocyte
necrosis and liver cell renewal coupled with inflammation,
which is characteristic of chronic viral hepatitis, causes not
only cirrhosis but also progressive genomic errors in hepato-
cytes as well as unregulated growth and repair mechanism
leading to hepatocyte dysplasia and, in some cases, HCC
(15). Investigation of the cell proliferating status in HCC is
important for evaluating the biological aggressiveness of
HCC, because distant and lymphatic metastases are not
very common. Recently, both genetic alterations and over-
expressions of cell cycle modulators in HCC have been
investigated, but there were small numbers of cases with
hepatitis B virus (HBV)-related HCC (16-18). HBV-related
HCC constitutes about 65-70% of HCC in Korea (19). It is
necessary to study on the cell cycle modulators for a large
number of cases with HBV-related HCC for the prevention
and treatment of HCC.
Dysplastic nodule (DN) has recently been described as
possible precancerous lesion in multistep hepatocarcinogen-
esis (20). Sequential development of low grade DN (LDN),
high grade DN (HDN) and early HCC is very similar to
multistep tumorigenesis in colon (21). In colorectal carcino-
genesis, p53 mutation occurs in about 20% of adenomas
and seems to be a rate-limiting step that makes an impor-
tant contribution to tumor progression (22). p53 mutation
might be an unusual event in DN (23). No crucial events or
pivotal alterations in the molecular basis of the hepatocar-
cinogenesis have yet to be elucidated. 
The aims of this study were to evaluate the expressions of
cyclin D1, cyclin E, p53, p27, p21, p16, Rb, and PCNA
proteins in HBV-related HCCs and DNs with a correlation
with the histopathologic features of HCCs.
MATERIALS AND METHODS
Tissue specimens and histopathology
Eighty HCCs (Edmondson grade I, 20; grade II, 24;
grade III, 36 cases) and 22 DNs (LDN, 10; HDN, 12 cases)
were derived from 72 and 18 surgically resected livers,
respectively, at Samsung Medical Center from 1996 to
1999. All patients were of Korean origin. The patients were
diagnosed as HCC or liver cirrhosis, and undergone surgery
without transcatheter arterial chemoembolization or lipi-
odol injection. All patients were seropositive for hepatitis B
surface antigen (HBsAg), showed positive immunoreactivi-
ty for HBsAg in nontumorous liver, and had no serum anti-
body against hepatitis C virus (HCV). Seventy two patients
with HCC were 58 men and 14 women with a mean age at
diagnosis of 55.2 yr (range, 31-79 yr). Eighteen patients
with DN were 16 men and 2 women with a mean age at
diagnosis of 56.1 yr (range, 33-79 yr). Tissue were fixed in
10% formalin for 12 hr and embedded in paraffin. Sections
of 4- m thickness were stained with hematoxylin and
eosin. HCCs were graded histologically according to the
Edmondson and Steiner (24), and DNs were classified
according to the International Working Party (20) into two
groups, i.e., LDN and HDN. Among the patients with
HCC, 67 patients had single HCC, 2 patients had two
HCCs, and 3 patients had three HCCs. Among the patients
with DN, 15 patients had single DN, 2 patients had two
DNs, and 1 patient had three DNs. Among the patients
with HCC, 56 patients showed cirrhosis in nontumorous
liver, and 16 patients showed chronic hepatitis. All patients
with DN showed cirrhosis in nontumorous liver, and five
patients with DN had no HCC. The histopathologic fea-
tures of HCCs were examined: tumor stage, tumor size, his-
tological differentiation, portal vein invasion, microvascular
invasion, intrahepatic metastasis, tumor capsule formation,
and growth pattern. The tumor stage was determined
according to the TNM atlas (UICC) (25). Portal vein inva-
sion was defined as tumor thrombus in the lobar or seg-
mental branches of the portal veins. Microvascular invasion
was considered as present when tumor was seen in a vessel,
that is, at least 1 or more endothelial cells or the tunica
media of the vessel were recognized to surround a neoplastic
cell group. Intrahepatic metastasis and tumor capsule for-
mation conformed to the Classification of Primary Liver
Cancer of the Liver Cancer Study Group of Japan (26). The
growth pattern was divided as infiltrative and expansive,
and infiltrative pattern was defined as the presence of one or
more foci of microscopic parenchymal invasion. Blocks of
normal liver were prepared from 10 patients with metastat-
ic colonic carcinoma of the liver as control cases.
Immunohistochemistry
Representative tissue sections including both HCC or
DN and adjacent nontumorous liver were selected and sec-
tioned in 4- m thickness. Immunohistochemical study was
performed using the streptavidin-biotin complex method
and TechMate
TM 1,000 automated staining system (Dako
Chemmate, Glostrup, Denmark). Primary antibodies usedand working dilutions employed were as follows: cyclin D1
(clone P2D11F11, monoclonal, 1:10), cyclin E (clone 13A3,
monoclonal, 1:20), and Rb (clone 1F8, monoclonal, 1:20)
from Novocastra (London, UK), p21 (clone SX118, mono-
clonal, 1:25) and PCNA (clone PC10, monoclonal, 1:1000)
from Dako (Glostrup, Denmark), p53 (clone BP53.12, mono-
clonal, 1:80), p27 (clone 57, monoclonal, 1:200), and p16
(rabbit polyclonal, 1:20) from Zymed (San Francisco, CA,
U.S.A.), Transduction (Lexington, KY, U.S.A.), and Santa
Cruz (Santa Cruz, CA, U.S.A.), respectively. Deparaffinized
sections were treated with 3% hydrogen peroxide in metha-
nol for 10 min to block endogenous peroxidase. Sections
were processed in 0.05 M citrate buffer (pH 6.0) and heated
in a microwave oven for 10 min for antigen retrieval. Sec-
tions were then incubated with the primary antibody for 60
min at room temperature. Each section was treated with
biotinylated secondary antibody and streptavidin-peroxi-
dase complex (Dako, Glostrup, Denmark), sequentially.
DAB (3,3′ -diaminobenzidine tetrahydrochloride) was used
as a chromogen, and Mayer’s hematoxylin counterstain was
applied. Negative controls were run simultaneously with an
omission of primary antibody. 
Immunohistochemical evaluation
For assessment of the positivity of immunostaining for
each section, only nuclear staining was regarded as positive.
We regarded the G1 cyclins and p53 as positive when ≥
5% of tumor cell nuclei showed positive immunostaining.
We counted positive cells for p27, p21, p16, Rb and PCNA
by monitoring at least 1,000 cells in HCC or DN and non-
tumorous liver from more than five high power fields where
positive cells were present at a relatively uniform density.
Then, we calculated the labeling index (LI) as a percentage
for each protein.
Statistical analyses
Values were expressed as mean±SD. Testing for associa-
tions between the expression of proteins and histopatholog-
ic parameters was performed by Chi-square analysis. When
appropriate, the unpaired Student t-test was used to test for
statistical differences between groups. p-values of less than
0.05 were considered statistically significant. 
RESULTS
Lymphocytes in nontumorous liver were positive for all
proteins, which were regarded as internal positive controls
for each section.
Cyclin D1 protein was overexpressed in 17 of the 80 cases
(21.3%) of HCC (Fig. 1A). Overexpression of cyclin D1
protein was significantly associated with advanced tumor
stage (p=0.032), larger tumor size (p=0.021), poorer histo-
logical grade of differentiation (p<0.0001), microvascular
invasion (p=0.023), intrahepatic metastasis (p=0.049), no
tumor capsule formation (p=0.003), infiltrative growth
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p value Categories Cyclin D1 positive cases
Tumor stage I 2/27 (7.4%) 0.032
II 3/21 (14.3%)
III 7/20 (35.0%)
IV 5/12 (41.7%)
Tumor size �2 cm 2/32 (6.3%) 0.021
2-5 cm 7/26 (26.9%)
>5 cm 8/22 (36.4%)
Differentiation Ed I 0/20 (0%) <0.001
Ed II 2/24 (8.3%)
Ed III 15/36 (41.7%)
Portal vein + 3/10 (30.0%) NS
invasion - 14/70 (20.0%)
Microvascular + 12/37 (32.4%) 0.023
invasion - 5/43 (11.6%)
Intrahepatic + 5/11 (45.5%) 0.049
metastasis - 12/69 (17.4%)
Capsule + 3/37 (8.1%) 0.003
formation - 14/38 (36.8%)
Growth pattern Infiltrative 10/27 (37.0%) 0.016
Expansive 7/53 (13.2%)
p53 expression Positive 9/18 (50.0%) 0.002
Negative 8/62 (12.9%)
Table 1. Relationship between the overexpression of cyclin D1
protein and histopathologic features of hepatocellular carcinomas
Ed, Edmondson grade; NS, not significant
p value Categories p53 positive cases
Tumor stage I 2/27 (7.4%) NS
II 5/21 (23.8%)
III 7/20 (35.0%)
IV 4/12 (33.3%)
Tumor size �2 cm 2/32 (6.3%) NS
2-5 cm 9/26 (34.6%)
>5 cm 7/22 (31.8%)
Differentiation Ed I 0/20 (0%) 0.003
Ed II 4/24 (16.7%)
Ed III 14/36 (38.9%)
Portal vein + 3/10 (30.0%) NS
invasion - 15/70 (21.4%)
Microvascular + 11/37 (29.7%) NS
invasion - 7/43 (16.3%)
Intrahepatic + 3/11 (27.3%) NS
metastasis - 15/69 (21.7%)
Capsule + 8/37 (21.6%) NS
formation - 10/38 (26.3%)
Growth pattern Infiltrative 8/27 (29.6%) NS
Expansive 10/53 (18.9%)
Table 2. Relationship between the aberrant expression of p53
protein and histopathologic features of hepatocellular carcinomas
Ed, Edmondson grade; NS, not significantG1-S Modulators in HBV-Related Hepatocellular Carcinoma 427
(p=0.016), and aberrant expression of p53 protein (p=0.002)
(Table 1). The average LI of PCNA was significantly higher
in cases with overexpression of cyclin D1 protein (cyclin D1
positive: 76.0±16.0, cyclin D1 negative: 56.3±27.0, p=
0.018).
Only one case (1.3%) of stage III HCC showed overex-
pression of cyclin E protein (Fig. 1B).
Aberrant expression of p53 protein was observed in 18 of
the 80 cases (22.5%) of HCC (Fig. 1C). There was positive
correlation between the aberrant expression of p53 protein
and poorer histological grade of differentiation (p=0.003)
(Table 2). The average LI of PCNA was higher in cases with
aberrant p53 protein expression, but there was no statistical
significance (p=0.076).
Expression of cyclin D1, cyclin E, and p53 proteins was
not observed in DNs, nontumorous livers, and normal con-
trols.
p27 protein was expressed in 64 cases (80%) of HCC
E F
C D
A B
Fig. 1. Representative examples of immunohistochemical staining of the G1-S modulators in HCCs (A-D, F, G, I) and dysplastic nodules (E,
H, J). Overexpression of cyclin D1 (A) and cyclin E (B), and aberrant expression of p53 (C) in HCCs Ed III. Nuclear immunoreactivity for p27
in HCC Ed II (D) and high grade dysplastic nodule (E). Nuclear immunoreactivity for p21 in HCC Ed III (F). (Fig. 1 continued next)428 Y.-L. Choi, S.H. Park, J.-J. Jang, et al.
(Fig. 1D) and its average LI was 45.3±38.4. The p27 LI in
HCC was significantly lower in cases with intrahepatic
metastasis (p=0.040) (Table 3). p27 protein was expressed
in 6 of the 12 cases (50%) of HDN (Fig. 1E) and 6 of the
10 cases (60%) of LDN. The average LIs of HDN, LDN,
and nontumorous liver were 7.0±11.9, 3.0±4.1, and 8.0
±18.2, respectively (Table 5), and were significantly lower
than that of HCC (p<0.001).  
p21 protein was expressed in 18 cases (22.5%) of HCC
(Fig. 1F) and its average LI was 0.6±1.8. No correlation
could be established between the p21 LI and histopatholog-
ic features of HCCs, including aberrant expression of p53
protein (Table 3). p21 protein was not expressed in DNs
and nontumorous livers (Table 5).
p16 protein was expressed in 58 cases (72.5%) of HCC
(Fig. 1G) and its average LI was 35.2±37.4. p21 LI in
HCC was significantly lower in cases with intrahepatic
metastasis (p=0.012) (Table 3), and there was no association
with the pRb LI. p16 protein was expressed in 6 cases
(50%) of HDN (Fig. 1H) and 6 cases (60%) of LDN. The
average LIs of HDN, LDN, and nontumorous liver were
9.5±16.1, 1.8±2.1, and 9.0±23.8, respectively (Table 5),
and were significantly lower than that of HCC (p<0.001).
Rb protein was expressed in 62 cases (77.5%) of HCC
(Fig. 1I) and its average LI was 34.6±35.6. There was no
statistically significant correlation between the pRb LI and
histopathologic features of HCCs (Table 4). Rb protein was
expressed in 7 cases (58.3%) of HDN (Fig. 1J) and 5 cases
(50%) of LDN. The average LIs of HDN, LDN, and nontu-
morous liver were 17.5±21.4, 1.3±2.0, and 5.9±13.1,
respectively (Table 5), and were significantly lower than
that of HCC (p<0.05).
The average PCNA LIs of nontumorous liver, LDN,
HDN, and HCC were 2.3±1.2, 3.8±2.6, 10.0±9.7, and
33.3±21.7 (Edmondson I, 10.1±7.1; Edmondson II, 23.6
±12.4; Edmondson III, 43.3±21.2), respectively (Table
5). The PCNA LI significantly increased from LDN to
HDN, and from HDN to HCC (p<0.001). The PCNA LI
in HCC was significantly higher in more poorly differentiat-
ed lesions (p=0.000).
There were no significant differences between the average
LI of p27, p21, p16, and Rb proteins in nontumorous liver
and those in normal controls.
I J
G H
Fig. 1. (Continued from the previous page) Nuclear immunoreactivity for p16 in HCC Ed II (G) and high grade dysplastic nodule (H). Nucle-
ar immunoreactivity for Rb in HCC Ed II (I) and high grade dysplastic nodule (J). (×200). Ed: Edmondson grade.G1-S Modulators in HBV-Related Hepatocellular Carcinoma 429
DISCUSSION
Hepatitis B virus is an important etiologic factor that
contributes to HCC, but there have been few studies for a
large number of cases with HBV-related HCC. Nishida et
al. (27) demonstrated that amplification and overexpression
of cyclin D1 gene in both HBV- and HCV-related HCCs at
an advanced stage with rapid tumor growth. However, a
recent study reported that downregulation of cyclin D1
mRNA was significantly associated with large HCC and
did not correlate with serum HBsAg (18). Ito et al. (16)
reported that cyclin D1 protein overexpression occurred
more frequently in HCCs with poor differentiation (p=
0.0612) and intrahepatic metastasis (p=0.0675), and did
not correlate with serum HBsAg or HCV antibody. In this
study, overexpression of cyclin D1 protein showed positive
relationship with advanced tumor stage, poor differentia-
tion, larger tumor size, microvascular invasion, intrahepatic
metastasis, no tumor capsule formation, and infiltrative
growth of HBV-related HCCs. But cyclin D1 protein over-
expression was not observed in DNs. Our findings strongly
suggest that cyclin D1 protein overexpression occurs after
the initial stage of hepatocellular carcinogenesis, and reflects
the progression and aggressiveness of HBV-related HCCs.
Cyclin D1 alterations might be an unusual event in DNs,
and might have a less crucial role in the DN-HCC sequence.
p value Categories Rb LI
Tumor stage I 24.0±26.7 NS
II 43.9±44.2
III 34.2±38.2
IV 39.7±35.9
Tumor size �2 cm 27.8±29.1 NS
2-5 cm 39.2±33.3
>5 cm 40.3±46.2
Differentiation Ed I 26.2±29.7 NS
Ed II 39.7±38.3
Ed III 35.8±32.2
Portal vein + 46.0±48.5 NS
invasion - 33.1±33.5
Microvascular + 37.9±39.1 NS
invasion - 32.2±29.4
Intrahepatic + 15.8±11.1 NS
metastasis - 37.2±42.0
Capsule + 36.7±38.8 NS
formation - 33.6±35.9
Growth pattern Infiltrative 33.3±29.9 NS
Expansive 35.3±40.1
Table 4. Relationship between the expression of Rb protein
and histopathologic features of hepatocellular carcinomas
LI, labeling index; Ed, Edmondson grade; NS, not significant
HCC 45.3 0.6 35.2 34.6 33.3
HDN 7.0 0 9.5 17.5 10.0
LDN 3.0 0 1.8 1.3 3.8
p27 LI p21 LI p16 LI PCNA LI Rb LI
Table 5. Average labeling indices of p27, p21, p16, Rb, and
PCNA proteins in hepatocellular carcinomas and dysplastic
nodules
HCC, hepatocellular carcinoma; HDN, high grade dysplastic nodule;
LDN, low grade dysplastic nodule; LI, labeling index
p value p value p value Categories p27 LI p21 LI p16 LI
Tumor stage I 29.4±21.2 NS 0.2±0.8 NS 31.3±28.9 NS
II 61.3±63.0 0.1±0.3 42.8±39.5
III 50.2±44.3 0.5±0.8 40.0±42.2
IV 38.3±33.2 2.1±1.9 23.0±29.1
Tumor size �2 cm 37.2±39.1 NS 0.2±0.3 NS 37.1±34.3 NS
2-5 cm 45.6±44.9 0.5±0.8 30.7±33.2
>5 cm 54.3±52.2 1.1±2.1 38.3±35.5
Differentiation Ed I 38.5±41.5 NS 0.1±0.7 NS 35.5±37.2 NS
Ed II 53.1±55.1 0.3±0.4 37.9±40.9
Ed III 43.8±33.3 1.0±0.7 33.3±31.6
Portal vein + 38.0±40.4 NS 2.1±3.1 NS 6.0±11.1 NS
invasion - 46.6±37.8 0.3±0.9 36.9±32.3
Microvascular + 49.2±47.2 NS 0.2±0.5 NS 37.0±39.0 NS
invasion - 42.1±39.2 1.0±0.4 33.8±31.7
Intrahepatic + 15.8±19.5 0.040 0.6±0.7 NS 9.2±12.1 0.012
metastasis - 50.5±47.2 0.6±0.6 39.8±34.1
Capsule + 47.6±42.9 NS 0.9±1.1 NS 39.2±30.2 NS
formation - 46.3±44.2 0.2±0.3 34.2±33.6
Growth pattern Infiltrative 42.0±40.8 NS 0.3±0.4 NS 29.0±34.3 NS
Expansive 47.0±39.6 1.2±2.1 38.6±39.1
Table 3. Relationship between the expression of p27, p21 and p16 proteins, and histopathologic features of hepatocellular carcinomas 
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We also found that overexpression of cyclin D1 protein was
significantly associated with aberrant expression of p53 pro-
tein, which suggests that overexpression of cyclin D1 and
p53 proteins can lead to deregulation of cell cycle and con-
tribute to the progression of HBV-related HCC. The PCNA
LI was higher in HCCs with overexpression of cyclin D1
protein, which suggests that cyclin D1 protein is related to
the dedifferentiation and proliferative activity of HBV-relat-
ed HCCs.
In this study, the histological differentiation of HCCs cor-
related with the aberrant p53 protein expression, and there
was no p53 protein expression in DNs. We suggest that
p53 alterations may be an unusual event in the precancer-
ous lesions of multistep hepatocarcinogenesis, and might
have a less crucial role in the DN-HCC sequence. p53 alter-
ations seem to be a relatively late occurring event and relat-
ed to the aggressiveness of HCC (16). And it is suggested
that p53 alterations play a less important role in the pro-
gression of HBV-related HCCs than cyclin D1 alterations.
Peng et al. (18) reported that overexpression of cyclin E
mRNA was observed in 56.3% of HCC, was significantly
associated with poorly differentiated and invasive HCCs,
and did not correlate with serum HBsAg. Ito et al. (16)
reported that cyclin E protein overexpression was observed
in 35.5% of HCC, and had positive relationship with stage
of HCC. In the present study, cyclin E protein overexpres-
sion was observed in 1.3% of HCC. Since the histopatho-
logic features do not differ in HCCs from various geograph-
ic areas, the discrepancy in frequency of cyclin E alterations
may indicate that these changes do not represent a primary
oncogenic event but are a late event in tumor progression.
Alternatively, the existence of a different genetic back-
ground for the etiology of HCCs in different human popu-
lations could be postulated.
p27 protein is expressed in high rate in normal tissue,
but shows decrease or absence of expression in tumor tissue,
indicating an unfavorable factor in human cancers (28-30).
In this study, the average LI of p27 protein was higher in
HCC than in nontumorous liver or DN, unlike other can-
cers. Our finding is consistent with the recent report (16).
We found that the p27 LI was significantly lower in HCCs
with intrahepatic metastasis (p=0.040). This study offers
the evidence for a potential role of p27 dysfunction in the
process of HCC metastasis. Ito et al. (16) reported that the
decreased expression of p27 protein in HCC was strikingly
related to the biological aggressiveness, including portal
vein invasion, poor differentiation, and larger size of HCCs
as well as its prognosis, and that the p27 LI decreased with
borderline significance in cases with intrahepatic metastasis
(p=0.078). A previous study demonstrated that the lack or
decreased expression of this protein is regulated at posttrans-
lational levels of p27 gene by a ubiquitin-proteosome path-
way (31), instead of common gene mutations or aberrant
DNA methylation. The decreased p27 protein expression in
advanced HCC may be derived by the same mechanism.
Recent studies demonstrated that p21 is an important
cell cycle regulatory factor in continuously proliferating
cells. Little p21 protein or mRNA is detected in normal
human liver tissue, but hepatocyte p21 expression is upreg-
ulated in response to hepatic injury (32, 33). The absence of
p21 protein expression in nontumorous liver in this study
indicates that the level of p21 protein in hepatocytes is
below the immunohistochemically detectable threshold,
which might be due to the low proliferative activity in non-
tumorous liver. Down-regulation of p21 expression through
degradation by a ubiquitin-dependent proteolytic pathway
has recently been reported (34). Our results showed that the
average LI of p21 protein was very low in HCC, which sug-
gests that post-transcriptional regulation might be one
mechanism that down-regulate p21 expression in HCC. In
this study, there was no correlation between the p21 protein
expression and histopathologic features of HCCs, which is
consistent with the recent reports (35, 36).
A recent study demonstrated that epigenetic change due
to extensive CpG methylation is the main cause of inactiva-
tion of p16(INK4a) in HCC (37). In this study, the average
LI of p16 protein was higher in HCC than in nontumorous
liver, which is consistent with the recent report (16). We
demonstrated that the p16 LI was significantly lower in
HCCs with intrahepatic metastasis (p=0.012). This study
offers the evidence for a potential role of p16 dysfunction in
the process of HCC metastasis. Hui et al. (38) suggested
that p16 protein loss might contribute to the progression of
HCC, because it occurred approximately twice as often in
advanced rather than in early stage HCC.
The loss of pRb expression in HCC is mainly caused by
loss of heterozygosity of the Rb gene (39). In this study, the
average LI of pRb was higher in HCC than in nontumorous
liver, which is consistent with the recent report (16). Hui et
al. (40) suggested that elevated and absent pRb is closely
associated with tumor progression and developing metasta-
tic disease rather than tumor initiation in HCC. We could
not determine any correlation between the pRb expression
and histopathologic features of HCCs, which is consistent
with previous reports (16, 41). 
The PCNA LI, in this study, was significantly higher in
more poorly differentiated HCCs, which is consistent with
previous reports (42, 43). Our finding suggests that cell
proliferative activity of HCC cells correlates with their
degree of dedifferentiation. We also found that the PCNA
LI increased from LDN, to HDN, and to HCC, which is
consistent with previous report (43).
In summary, the present study suggests that overexpres-
sion of cyclin D1 protein and aberrant expression of p53
protein could be associated with the progression of HBV-
related HCC, but might not be related to the DN-HCC
sequence. In addition, elevated expression of p27 and p16
proteins might have inhibitory action to the intrahepaticmetastasis of HBV-related HCC. 
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